147 related articles for article (PubMed ID: 30041149)
1. Predicting response to sepantronium bromide (YM155), a survivin suppressant, by PET imaging with [
Mitsuoka K; Kita A; Murakami Y; Shirasuna K; Noda A; Yamanaka K; Kaneko N; Miyoshi S
Nucl Med Biol; 2018; 64-65():41-46. PubMed ID: 30041149
[TBL] [Abstract][Full Text] [Related]
2. Radiosynthesis, biodistribution and imaging of [11C]YM155, a novel survivin suppressant, in a human prostate tumor-xenograft mouse model.
Murakami Y; Matsuya T; Kita A; Yamanaka K; Noda A; Mitsuoka K; Nakahara T; Miyoshi S; Nishimura S
Nucl Med Biol; 2013 Feb; 40(2):221-6. PubMed ID: 23141550
[TBL] [Abstract][Full Text] [Related]
3. Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells.
Minematsu T; Iwai M; Sugimoto K; Shirai N; Nakahara T; Usui T; Kamimura H
Drug Metab Dispos; 2009 Mar; 37(3):619-28. PubMed ID: 19056913
[TBL] [Abstract][Full Text] [Related]
4. Formulation design and evaluation of liposomal sepantronium bromide (YM155), a small-molecule survivin suppressant, based on pharmacokinetic modeling and simulation.
Shakushiro K; Kawano H; Nakata M; Kita A; Maeda A; Watanabe S; Sako K; Oku N
Pharm Res; 2015 Jan; 32(1):238-47. PubMed ID: 25033765
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant.
Kawano H; Shakushiro K; Nakata M; Kita A; Maeda A; Watanabe S; Sako K; Oku N
Eur J Pharm Biopharm; 2014 Sep; 88(1):283-9. PubMed ID: 24993306
[TBL] [Abstract][Full Text] [Related]
6. Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells.
Gholizadeh S; Dolman EM; Wieriks R; Sparidans RW; Hennink WE; Kok RJ
Pharm Res; 2018 Mar; 35(4):85. PubMed ID: 29516187
[TBL] [Abstract][Full Text] [Related]
7. Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma.
Zhang L; Zhang W; Wang YF; Liu B; Zhang WF; Zhao YF; Kulkarni AB; Sun ZJ
Cell Death Dis; 2015 May; 6(5):e1771. PubMed ID: 26018732
[TBL] [Abstract][Full Text] [Related]
8. Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab.
Kita A; Mitsuoka K; Kaneko N; Nakata M; Yamanaka K; Jitsuoka M; Miyoshi S; Noda A; Mori M; Nakahara T; Sasamata M
J Pharmacol Exp Ther; 2012 Oct; 343(1):178-83. PubMed ID: 22787117
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
[TBL] [Abstract][Full Text] [Related]
10. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.
Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Hatakeyama S; Kinoyama I; Matsuhisa A; Kudoh M; Sasamata M
Cancer Res; 2007 Sep; 67(17):8014-21. PubMed ID: 17804712
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of sepantronium bromide YM155 in gemcitabine-resistant human urothelial carcinoma cells.
Huang YT; Cheng CC; Lin TC; Chiu TH; Lai PC
Oncol Rep; 2014 Feb; 31(2):771-80. PubMed ID: 24297644
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic modeling of sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma.
Aoyama Y; Kaibara A; Takada A; Nishimura T; Katashima M; Sawamoto T
Invest New Drugs; 2013 Apr; 31(2):443-51. PubMed ID: 22892872
[TBL] [Abstract][Full Text] [Related]
13. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.
Nakahara T; Yamanaka K; Hatakeyama S; Kita A; Takeuchi M; Kinoyama I; Matsuhisa A; Nakano K; Shishido T; Koutoku H; Sasamata M
Anticancer Drugs; 2011 Jun; 22(5):454-62. PubMed ID: 21389848
[TBL] [Abstract][Full Text] [Related]
14. Targeting survivin with YM155 (Sepantronium Bromide): a novel therapeutic strategy for paediatric acute myeloid leukaemia.
Smith AM; Little EB; Zivanovic A; Hong P; Liu AK; Burow R; Stinson C; Hallahan AR; Moore AS
Leuk Res; 2015 Apr; 39(4):435-44. PubMed ID: 25659731
[TBL] [Abstract][Full Text] [Related]
15. Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant.
Minematsu T; Iwai M; Umehara K; Usui T; Kamimura H
Drug Metab Dispos; 2010 Jan; 38(1):1-4. PubMed ID: 19833842
[TBL] [Abstract][Full Text] [Related]
16. Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.
Wagner V; Hose D; Seckinger A; Weiz L; Meißner T; Rème T; Breitkreutz I; Podar K; Ho AD; Goldschmidt H; Krämer A; Klein B; Raab MS
Oncotarget; 2014 Nov; 5(21):10237-50. PubMed ID: 25296978
[TBL] [Abstract][Full Text] [Related]
17. YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer.
Yamanaka K; Nakata M; Kaneko N; Fushiki H; Kita A; Nakahara T; Koutoku H; Sasamata M
Int J Oncol; 2011 Sep; 39(3):569-75. PubMed ID: 21674125
[TBL] [Abstract][Full Text] [Related]
18. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models.
Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Kinoyama I; Matsuhisa A; Kudou M; Sasamata M
Cancer Sci; 2011 Mar; 102(3):614-21. PubMed ID: 21205082
[TBL] [Abstract][Full Text] [Related]
19. Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells.
Liang H; Zhang L; Xu R; Ju XL
Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2909-15. PubMed ID: 24254560
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
